HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

L’Oreal’s Microbiome Explorations Lead To Micreos Deal For Next-Gen Antibacterial

Executive Summary

“We expect this partnership to be groundbreaking,” says Mark Offerhaus, CEO of Micreos, which will provide L’Oreal with its proprietary endolysin, which selectively destroys microorganisms associated with skin problems while leaving beneficial bacteria intact.

You may also be interested in...



ASA On Baby Dove Microbiome Claims: Unilever’s Evidence Comes Up Short

Unilever’s in vitro and clinical studies examining the effects of glycerol, an ingredient in Baby Dove wash and lotion, were inadequate to substantiate microbiome claims as consumers are likely to understand them, according to a 13 January decision from the UK-based Advertising Standards Authority.

L’Oreal’s Mid-COVID Bet Pays Off With Q3 Return To Growth

With many competitor programs on hold during the COVID crisis, L’Oreal dialed up its media investments and launched products over the summer that were postponed from the first quarter, resulting in a return to growth in the firm’s third quarter led by Professional Products and Active Cosmetics.

Dutch Biotech Touts Enzyme-Powered Eczema Cream As ‘Smarter And Safer’ Solution

Headquartered in The Hague, Netherlands, Micreos is focused on developing targeted antibacterial products to replace antibiotics, protect against food contamination and treat inflammatory skin conditions. The firm’s Gladskin Eczema Cream, now available stateside, uses a patented enzyme technology to destroy Staphylococcus aureus bacteria while leaving skin’s beneficial flora intact.  

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150638

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel